We are now recruiting participants for the LIBERTY‑ABPA AIRED study, a clinical research study to test whether an investigational medication helps adults and adolescents aged 12 years and older with ABPA to decrease episodes of severe breathing difficulties. The study will also look at the long‑term safety of the investigational medication.
The LIBERTY‑ABPA AIRED study consists of a 4‑week screening period to determine eligibility, followed by a treatment period and a safety follow‑up period. The treatment period lasts approximately 52 weeks, with a safety follow‑up within 12 weeks after treatment ends.
The treatment period is double‑blind, which means the participants and the study team, including site staff, will not know whether the participants are receiving the investigational medication or placebo.
During the double‑blind period, participants will be randomized (by chance, like a flip of a coin) to either taking the investigational medication or placebo every 2 weeks for 52 weeks.
Qualified participants may receive:
- Reimbursement for patient travel expenses.
Consider the LIBERTY-ABPA AIRED study
The site study team can answer any questions you may have about the clinical study and what participation would involve.
To learn more and/or determine eligibility for the LIBERTY-ABPA AIRED study:
This post is sponsored by Regeneron.